Your browser doesn't support javascript.
loading
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.
Gauthier, Jordan; Gazeau, Nicolas; Hirayama, Alexandre V; Hill, Joshua A; Wu, Vicky; Cearley, Aisling; Perkins, Paula; Kirk, Angela; Shadman, Mazyar; Chow, Victor A; Gopal, Ajay K; Hodges Dwinal, Alexandria; Williamson, Staci; Myers, Jessie; Chen, Andy; Nagle, Sarah; Hayes-Lattin, Brandon; Schachter, Levanto; Maloney, David G; Turtle, Cameron J; Sorror, Mohamed L; Maziarz, Richard T.
Afiliación
  • Gauthier J; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
  • Gazeau N; Department of Medicine, University of Washington, Seattle, WA; and.
  • Hirayama AV; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
  • Hill JA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
  • Wu V; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
  • Cearley A; Department of Medicine, University of Washington, Seattle, WA; and.
  • Perkins P; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
  • Kirk A; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
  • Shadman M; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
  • Chow VA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
  • Gopal AK; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
  • Hodges Dwinal A; Department of Medicine, University of Washington, Seattle, WA; and.
  • Williamson S; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
  • Myers J; Department of Medicine, University of Washington, Seattle, WA; and.
  • Chen A; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
  • Nagle S; Department of Medicine, University of Washington, Seattle, WA; and.
  • Hayes-Lattin B; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
  • Schachter L; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
  • Maloney DG; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
  • Turtle CJ; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
  • Sorror ML; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
  • Maziarz RT; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
Blood ; 139(26): 3722-3731, 2022 06 30.
Article en En | MEDLINE | ID: mdl-35439295
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Linfoma de Células B Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Blood Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Linfoma de Células B Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Blood Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos